Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5698334 | Clinical Oncology | 2017 | 8 Pages |
Abstract
HPA dysfunction in patients treated for non-pituitary intracranial neoplasms is probably a result of both neurosurgery and radiotherapy treatments. Although statistically significant endocrine changes can occur during this first year of follow-up, those documented at year 1 may be more predictive of subsequent HPA dysfunction.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
N. Taku, M. Gurnell, N. Burnet, R. Jena,